LQDA
NCM 股策精挑入选日 2026-05-13 · 入选 46 天AI选股记录
热门股票选股 #2 评分 84 概率 69%这个股票来自自动 AI 选股池。以后只要 CLI 写入新的 ticker，这里会自动生成个股页面，不需要手工补页面。
成交量、价格变化和流动性更突出，适合作为热门观察池候选。
基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | 综合评分 | 61 | $71.07 | $63.96 | $85.28 | +10.0% | 可买入 |
| 2026-06-22 | 动量强势 | +77.1% | $71.07 | $62.96 | $87.28 | +10.0% | 可买入 |
| 2026-06-04 | 综合评分 | 69 | $64.42 | $57.98 | $77.30 | +21.3% | 可买入 |
| 2026-06-04 | 动量强势 | +76.8% | $64.42 | $56.69 | $79.88 | +21.3% | 可买入 |
| 2026-06-01 | 综合评分 | 64 | $61.86 | $55.67 | $74.23 | +26.4% | 可买入 |
| 2026-06-01 | 动量强势 | +89.7% | $61.86 | $54.44 | $76.71 | +26.4% | 可买入 |
| 2026-05-30 | 动量强势 | +89.7% | $61.86 | $54.44 | $76.71 | +26.4% | 可买入 |
| 2026-05-29 | 综合评分 | 64 | $62.03 | $55.83 | $74.44 | +26.0% | 可买入 |
| 2026-05-29 | 动量强势 | +90.5% | $62.03 | $54.59 | $76.92 | +26.0% | 可买入 |
| 2026-05-28 | 动量强势 | +91.1% | $62.02 | $54.58 | $76.91 | +26.0% | 可买入 |
公司简介
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
最新资讯
